PRISMA Study

Phase II (RAINBOW) PRISMA Study

PRISMA is an open-label Phase II extension study following the RAINBOW trial, evaluating the longer-term safety and effects of nizubaglustat in patients with GM2 gangliosidosis and Niemann-Pick type C disease. The study includes participants who completed RAINBOW, as well as additional patients, and aims to further assess treatment outcomes over time.

The study is ongoing and continues to generate data to support the clinical development of nizubaglustat.

More information?

If you have any questions about this study, please Get in touch.